Jasper Therapeutics, Inc., (JSPR): Price and Financial Metrics


Jasper Therapeutics, Inc., (JSPR): $1.74

-0.06 (-3.33%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add JSPR to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

JSPR Stock Price Chart Interactive Chart >

Price chart for JSPR

JSPR Price/Volume Stats

Current price $1.74 52-week high $5.81
Prev. close $1.80 52-week low $0.39
Day low $1.72 Volume 1,073,872
Day high $1.81 Avg. volume 10,522,528
50-day MA $1.03 Dividend yield N/A
200-day MA $1.73 Market Cap 66.09M

Jasper Therapeutics, Inc., (JSPR) Company Bio


Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company develops JSP191, a humanized monoclonal antibody for clearing hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation. It also develops Jasper eHSC Platform to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.


JSPR Latest News Stream


Event/Time News Detail
Loading, please wait...

JSPR Latest Social Stream


Loading social stream, please wait...

View Full JSPR Social Stream

Latest JSPR News From Around the Web

Below are the latest news stories about JASPER THERAPEUTICS INC that investors may wish to consider to help them evaluate JSPR as an investment opportunity.

Jasper Therapeutics Announces Pricing of $90 Million Public Offering of Common Stock

REDWOOD CITY, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, announced today the pricing of its underwritten public offering of 60,000,000 shares of its common stock. Each shar

Yahoo | January 25, 2023

Jasper Therapeutics Announces Proposed Public Offering of Common Stock

REDWOOD CITY, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, announced today that it intends to offer and sell, subject to market and other conditions, shares of its common sto

Yahoo | January 24, 2023

Why Is Jasper Therapeutics (JSPR) Stock Up 50% Today?

JSPR stock is shooting higher as Jasper Therapeutics helps to combat the life-threatening impact of certain blood diseases.

David Moadel on InvestorPlace | January 13, 2023

APRN Stock Alert: Short Squeeze Takes Blue Apron Back Above $1

Blue Apron (APRN) stock has investors excited on Friday as the company's shares increased above the $1 NYSE minimum requirement.

William White on InvestorPlace | January 13, 2023

AVCT Stock Alert: Is American Virtual Cloud the Next Big Squeeze?

American Virtual Cloud Technologies (AVCT) stock is on the minds of traders with some wondering what's next for the company.

William White on InvestorPlace | January 13, 2023

Read More 'JSPR' Stories Here

JSPR Price Returns

1-mo 195.17%
3-mo 133.56%
6-mo -7.94%
1-year -60.09%
3-year -82.34%
5-year N/A
YTD 260.32%
2022 -93.85%
2021 -21.58%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7047 seconds.